This year's Editor's Choice highlights the 2023 publications in Thrombosis and Haemostasis (TH) and its open-access companion journal TH Open, focusing on manuscripts that have significantly resonated among our academic community.
Unlike previous years since 2020, this year marks a notable shift, with coronavirus
disease 2019 (COVID-19) papers no longer being in prime spotlight of TH publications.
Instead, we have observed a trend toward integration of COVID-19 research within the
broader context of cardiovascular studies.
Working against the Clot
Anticoagulation Management
The direct oral anticoagulants (DOACs) or nonvitamin K antagonist oral anticoagulants
(NOACs) are becoming the gold standard, gradually replacing vitamin K antagonists
and to some extent low molecular weight heparins. Beside the undeniable advantage
of oral administration, they are also offering more predictable dosing, and reduced
need for regular monitoring. Factor XIa (FXIa) inhibitors recently emerged as a yet
newer class of anticoagulants, which directly targets FXI in the coagulation cascade.
Galli et al[1] performed a useful pooled analysis gathering results from eight randomized controlled
trials testing these new anticoagulants, suggesting that FXIa inhibitors had increased
safety and efficacy in comparison to enoxaparin and even exhibited slightly enhanced
safety compared with other oral anticoagulants.
When exploring new promising treatments, customizing existing anticoagulation strategies
to align with patient's need is crucial. We have published several studies last year,
which investigated how age influences the management and efficacy of anticoagulation
therapy. The Adage Study collaborators[2] collected real-life setting pharmacokinetic/pharmacodynamics data on the oral FXa
inhibitors rivaroxaban and apixaban in aged atrial fibrillation (AF) patients. The
high variability in drug levels observed should prompt improvement in DOAC dosing
in this population. Tailored dosing strategy including information about genotype
and the concomitant use of interacting drug(s), may reduce variability in drug levels,
thereby improving clinical outcomes.[3]
The issue of polypharmacy, typically defined as the concomitant use of five or more
medications, is indeed particularly relevant in elderly patients with AF, often associated
with multiple health conditions, falls, frailty, and dementia. The study from Grymonprez
et al[4] confirmed worse outcomes including increased bleeding and mortality risks associated
with polypharmacy. NOACs demonstrated nonetheless superior benefit–risk profiles over
vitamin K antagonists in AF patients with polypharmacy, in agreement with the pooled
data meta-analysis on observational trials and post hoc subgroup analyses of randomized
clinical trials from Zheng et al.[5] These findings stress the importance of managing polypharmacy in AF patients to
enhance clinical care.
AF patients represent clinical complex patients,[6] and its management has evolved toward a holistic or integrated care approach, incorporating
stroke prevention, rate or rhythm control, and cardiovascular risk factor and comorbidity
management, including lifestyle factors.[7] Adhering to the recommended Atrial fibrillation Better Care pathway can significantly
impact AF outcomes, including mortality, stroke, and bleeding.[8]
[9] This approach is evident even in complex cases, and recommended in guidelines.[10]
[11]
Another issue is the clinical trial “underrepresentation” of elderly patients with
comorbid conditions associated with a high bleeding risk. The study from Schenker
et al[12] addressed this meaningful issue by investigating the large and well-known SWITCO65+
cohort of patients. They found that as much as one out of three patients could not
have participated in a therapeutic trial evaluating oral anticoagulant in the treatment
of acute venous thromboembolism (VTE), although this subpopulation has evolved a risk
profile different from the eligible patients, and an increased risk of major bleeding.
Such results should prompt clinicians to readdress VTE management in the elderly and
more particularly trialists to review the design of future studies.
Cirrhotic patients receiving DOACs represent another group of patients for whom bleeding
risk has not been systematically explored. Li et al[13] attempted to assemble the emerging evidence on this topic in an updated meta-analysis
study and reassuringly suggested that bleeding associated with DOACs was not significantly
elevated compared with other anticoagulants and might even be lower. With the advent
of improved oral anticoagulants and enhanced management approaches, it may become
possible to consider anticoagulation management in cases where it was not previously.
However, it is equally imperative to evaluate its benefits and risks in these scenarios.
While residual vein thrombosis has no role in patient management according to actual
international guidelines, a study by Iding et al[14] found that residual obstruction after deep vein thrombosis (DVT) indicated a higher
risk of postthrombotic syndrome which might prompt discussions on personalized care
for VTE patients.[15] Interestingly, the authors also observed higher risk of arterial events, hinting
at shared underlying mechanisms between venous fibrosis and atherosclerosis.
Another case where it is difficult to assess whether/how anticoagulation should be
considered is after intracranial hemorrhage. The lack of robust evidence from large,
randomized trials has led to uncertainty and thus, varying clinical practice on its
use.[16] Schulman and colleagues[17] presented a retrospective series of intracranial hemorrhage cases developing VTE
and suggested “stepwise escalation” of anticoagulation. Larger trials should offer
clarity on this topic in the upcoming years.[18]
Regular monitoring of anticoagulant activity is crucial for ensuring successful management
and safe administration of anticoagulation therapy. A French multicenter study[19] alerted to the significant overestimation of anti-Xa levels in anti-Xa assays using
dextran-containing reagents post heparin neutralization by protamine, warranting caution.
Adherence plays a pivotal role in the successful management of anticoagulants, significantly
influencing effectiveness and treatment outcomes. Examining anticoagulation treatment
patterns in South Korea, Yoon et al alerted us about country-specific obstacles to
anticoagulant therapy. They investigated the uptake and persistence of anticoagulants
in patients with and without cancer-related VTE in China between 2013 and 2019.[20] Their findings underscored a significant gap in treatment continuation, notably
in cancer-associated VTE cases, despite guidelines recommending indefinite anticoagulation,
which was likely attributable to lack of drug reimbursement and drug affordability
issues in China.[21]
Antiplatelet Strategies
As with anticoagulants, antiplatelet therapy effectively decreases the risk of thrombosis
but simultaneously elevates the risk of serious bleeding.[22] Dual-antiplatelet therapy (DAPT) intensifies this risk further, prompting studies
to explore shorter DAPT durations, particularly in stable patients. Such bleeding
risk is increased further among East Asians.[23]
[24] To address these issues, the systematic review and meta-analysis from Gorog et al[25] compared DAPT between East Asians and Western patients and highlighted that de-escalating
DAPT in East Asians indeed reduced bleeding without sacrificing the anti-ischemic
effect following acute coronary syndrome. The SWAP-AC Study[26] in turn offered significant evidence favoring the transition from DAPT to dual pathway
inhibition in patients with coronary artery disease. Birocchi et al[27] performed three meta-analyses cumulatively including 21 trials with P2PY12-related
therapy in patients undergoing percutaneous coronary intervention, which identified
genotype and high on treatment platelet reactivity as guidance for antiplatelet treatment,
most significantly in trials performed within China. This study should advance our
understanding of personalized antiplatelet therapy, particularly for Asian regions
characterized by elevated cytochrome P450 mutations.[28]
Amid the evolving landscape of COVID-19, exploring the potential of antiplatelet strategies
stands as a promising avenue in addressing the thrombotic complications associated
with this viral infection. Stefanini et al[29] reported higher sensitivity of platelets to ristocetin-induced agglutination in
severe and short-term mortality COVID-19 patients compared with patients with mild
symptoms, in line with previous observations on significant increase of von Willebrand
factors (VWFs) circulating levels in COVID-19 patients and could be a useful tool
to identify patients with high risk of clinical deterioration. Insights from the CORE-19
Registry revealed increased rates of arterial and VTE events, along with higher mortality
in COVID-19 patients with prior cardiovascular risks, calling for exploration of the
role of antithrombotic agents, particularly add-on antiplatelet therapy, through randomized
controlled trials in the immediate postdischarge period.[30] In this respect, Rolling et al's highly cited paper[31] on the effect of antiplatelet therapy P2Y12 inhibition in COVID-19 was very welcome.
Their findings align with previous studies in atherosclerosis patients, confirming
monocyte platelet aggregate formation and its successful suppression through P2Y12
inhibition in COVID-19. Exploring other treatment choices for COVID-19 patients was
also addressed by an extended follow-up of the (previously negative) INSPIRATION-S
trial (atorvastatin vs. placebo), involving critically ill COVID-19 patients in the
intensive care unit.[32]
Intravenous Thrombolysis
In certain acute conditions, where anticoagulation or antiplatelet strategies might
not suffice, actively dissolving blood clots becomes crucial, necessitating the use
of thrombolysis while carefully assessing its risks. In a large multicentric retrospective
observational study of acute ischemic stroke in China, Tu et al[33] addressed the debated efficacy of intravenous thrombolysis for minor stroke. Although
associated with an increased probability of functional independence at 3 months, intravenous
thrombolysis had no effect on mortality and appeared best reserved for people with
disabling deficits, while DAPT may be better adapted to patients with nondisabling
stroke syndromes.[34] In the context of DVT, catheter-directed thrombolysis is commonly used with insufficient
consensus on ideal patient selection and considerable variation in protocols and outcome
assessments. Duarte-Gamas et al[35] conducted a systematic review and meta-analysis to address this variability, which
underscored the need for standardized reporting in catheter-directed thrombolysis
protocols and patient-centered outcomes.[36]
At Risk!
Having mentioned numerous studies addressing risks primarily linked to anticoagulant
management, our scope now extends to additional pivotal risk factors implicated in
both thrombosis and stroke. These encompass critical aspects, including gender disparities,
the impact of obesity, previous thrombotic events, and the influence of various medical
conditions like cancer. These factors have been under investigation of the Italian
COPE study's report,[37] potentially the most extensive and contemporary on pulmonary embolism (PE) with
over 5,000 patients from more than 180 sites and which should serve as a valuable
data source on current disease patterns, management strategies, and outcomes of acute
PE.
Sex Differences
Female-specific biological factors, such as hormonal fluctuations during pregnancy,
contraceptive use, and hormonal therapies, contribute to an increased risk of thrombosis
and stroke. Understanding these distinctions is crucial for tailoring effective preventive
measures and treatments in women's health care and we are glad that many studies last
year reflected this important issue. The population level study from Hwang et al[38] on the occurrence of PE in pregnant women in Korea attracted particular attention.
Although Asian women generally have a reduced risk of pregnancy-associated VTE, this
risk is increasing, highlighting the importance for obstetricians to recognize VTE
risks, particularly among patients displaying clinical high-risk characteristics.[39] Insights from the Italian multicenter START Registry[40] shed light not only on pregnancy but also oral contraceptives as a risk factor for
VTE in women. The study underscored the importance of screening for a family history
of VTE in women of childbearing age, particularly those pregnant or using contraceptives.
Understanding these risk factors could aid in identifying at-risk women and guiding
counseling, alternative contraceptive choices, or thromboprophylaxis during high-risk
periods.[41]
The use of fertility drugs and hormones during assisted reproductive techniques is
another risk factor for women for developing blood clots. The study from Goualou et
al[42] emphasized how factors linked to infertility causes and drugs used in treatment
contribute to this risk. While assisted reproductive techniques' efficacy is continuously
enhanced, and becoming more common among older women with health issues, adequate
research on minimizing potential health risks for women are urgently required.[43]
Corica et al discussed female sex as a risk factor for AF-related stroke, as women
with AF still often receive less treatment with oral anticoagulants and suffer more
severe AF-related strokes. Inclusion of female sex in the CHA2DS2-VASc score has led to increased oral anticoagulant management in women, countering
the previous trend of lower anticoagulation usage among female AF patients.[44]
Weight
Obesity is a yet commonly recognized risk factor for VTE and an increasing relevant
issue that affects both initial VTE risk and recurrence risk. The Tromso Study group
used a large, population-based cohort to explore the population-attributable fraction
of VTE due to being overweight and obese[45] highlighting the importance of obesity in relation to VTE risk and adding to the
available information on the population-attributable risk of obesity with VTE. Emerging
research also explores the nuanced impact of body mass distribution on this condition,
highlighting complexities beyond overall body weight. Wang et al[46] investigated the link between waist circumference and hip circumference with VTE,
and particularly PE . They provided insights into visceral fat mass distribution as
an independent risk factor for VTE. Importantly, the study from Gaugler et al[47] reassuringly confirmed that body mass index did not impact the effectiveness of
age-adjusted D-dimer in patients suspected of having PE. While weight management may
prove beneficial in reducing the burden of VTE,[48] preventing obesity in the first place should become a priority.[49] Certain type of dieting that venous thrombosis patients may be attempting are also
associated with potential risks, as illustrated by the particularly intriguing case
report, of an individual who developed DVT complication while on a zero-calorie diet
regimen.[50]
Medical Conditions
Conditions such as AF and cancer also are pivotal contributors to the heightened risk
of thrombosis and stroke, often entwined with an increased susceptibility to bleeding
complications due to anticoagulant therapy. As there is to date still no clear evidence
on the clinical benefit of screening for AF, the exhaustive systematic review/meta-analysis
protocol description from randomized trials from McIntyre et al[51] was very welcome in shedding light on an interesting and still not well-elucidated
topic, namely, the impact of AF screening by electrocardiographic monitoring on stroke
prevention.
The study from Ryu et al[52] suggested that thromboelastography could predict functional outcomes in acute ischemic
stroke. They found a link between a hypercoagulable state (as identified by thromboelastography)
and poorer functional independence, symptomatic/asymptomatic hemorrhagic transformation,
and early neurological decline. While thromboelastography shows promise in managing
acute ischemic stroke, its definitive role in predicting outcomes requires further
validation through large-scale randomized trials.[53] Romiti et al[9] showcased the significant advantages of Mobile Health Technology for Improved Screening
and Optimized Integrated Care by a reanalysis of Atrial Fibrillation cluster randomized
trial (mAFA-II trial), using the win ratio approach, a methodology that presents certain
benefits compared with traditional analytical methods, particularly in trials evaluating
composite endpoints.
Individuals diagnosed with cancer have a higher likelihood of experiencing VTE due
to various factors, such as cancer-related inflammation and treatment methods. Assessing
the risk factors, implementing preventive measures, and evaluating whether anticoagulant
medications should be used are thus essential in cancer patients. In light of emerging
anticancer drugs such as immune checkpoint inhibitor therapy, the challenges facing
management of thrombotic and bleeding risks in cancer patients take a new dimension.
le Sève et al's study[54] highlighted the high VTE rate in cancer patients, mostly with lung cancer or melanoma,
undergoing immune checkpoint inhibitor therapy, primarily with nivolumab. This underscored
the emerging challenge of VTE with immune checkpoint inhibitor therapy, prompting
unanswered questions about its impact on survival, racial disparities, anticoagulant
use, bleeding risks, and the mechanisms of thromboembolism during treatment, which
require careful investigation, similar to previous generations of anticancer therapies.[55] In a prospective cohort with cancer-related VTE patients treated with anticoagulants,
McBane et al[56] underscored the impact of recurrent VTE and bleeding on overall mortality, not just
case fatality rate. Their data emphasized that anticoagulant-related bleeding is as
crucial as recurrent VTE in predicting mortality among patients with cancer-associated
VTE.[57] To address the specific need for predicting bleeding risk in patients with cancer-associated
VTE undergoing anticoagulant therapy, Cohen et al[58] introduced the B-CT score, based on a thorough analysis of real-world data from
over 15,000 patients with incident cancer-associated VTE patients treated with anticoagulants.
The novel score identified various factors associated with increased bleeding risk
in Ca-VTE patients, such as cancer type, history of bleeding, minor trauma, coagulation
disorders, and specific comorbidities like stroke and gastrointestinal disease.[59] Rønnow et al examined the risk of cancer in patients with kidney disease after experiencing
an initial VTE episode.[60] This study should alert physicians to be vigilant when focusing on kidney disease
alone, as it could point to additional comorbidities and should reinforce existing
guidelines recommending follow-up for patients 3 to 6 months postacute VTE potentially
including cancer screening.[61] Other studies assessed safety of specific anticoagulation management in cancer patients.
A retrospective review[62] indicated that both rivaroxaban and apixaban exhibited comparable effectiveness
and safety in treating cancer-associated thrombosis over a 6-month period, suggesting
the most suitable anticoagulant should be considered with regard to patient preferences,
adherence, and individual patient-specific factors.
Using data from the RIETE registry, Sigüenza et al[63] assessed the use of enoxaparin as a long-term treatment for VTE in cancer patients
with renal insufficiency and observed that as renal function declined the likelihood
of bleeding rose significantly, although the risk of recurrent VTE remained unchanged.
A less, well-commonly studied risk factor for VTE is apnea, particularly obstructive
sleep apnea, characterized by repeated episodes of upper airway obstruction during
sleep. Intermittent hypoxia and inflammatory pathway activation could contribute to
an increased risk of developing blood clots. Trzepizur et al[64] evaluated whether apnea markers were associated with unprovoked VTE incidence and
found that the time spent under 90% of saturation could independently predict the
risk of incident unprovoked VTE, but continuous positive airway pressure did unfortunately
not play a beneficial role in VTE risk in sleeping apnea patients.
(New) Techniques
We also welcomed new efforts into identifying or refining techniques to facilitate
the identification of thrombosis risks. The study from the PE-EHR+ investigators[65] proposed to focus on the validity of electronic health records and administrative
data analysis to identify acute PE patient cohorts. The PE-EHR+ study will be crucial
to assess international classification of diseases codes and natural language processing
methods for detecting acute PE hospitalizations. The meta-analysis from Squizzato
et al[66] highlighted the high sensitivity and specificity of ventilation/perfusion single-photon
emission computed tomography/computed tomography (V/Q SPECT/CT) lung scintigraphy
techniques in detecting acute PE. Despite recommendations favoring CT pulmonary angiography
as the gold standard offering greater anatomical detail, V/Q SPECT/CT might serve
as a “low radiation” tool in follow-ups for selected acute PE survivors or other specific
populations in stable conditions like pregnant women with suspected PE.[67]
Getting to the Heart of the Matter
Getting to the Heart of the Matter
Following our presentation of the most influential clinical papers published last
year, our focus now shifts to examining studies that investigated new mechanisms and
targets in cardiovascular health. The diverse range of papers published in this field
reflects the multifaceted nature and interconnected aspects of basic research published.
New Biomarkers and Prognostic Tools
Pedersen et al[68] evaluated the potential of circulating micro-ribonucleic acids for prognostic purposes
in a cohort of 900 stable patients with stable coronary artery disease and identified
circulating miR-223–3p as predictor of stent thrombosis and major adverse cardiovascular
event during follow-up, which may improve risk stratification in patients with stable
coronary artery disease. Using both clinical investigations and animal models, Liu
et al[69] identified neutrophil extracellular traps (NETs) as a thrombosis risk marker and
potential target for treatment in AF. However, it remains uncertain whether NETs play
a causal role in initiating thrombosis or are merely associated with thrombotic events.[70] Risk of bleeding was sought by Lahu et al[71] who identified an association with soluble glycoprotein VI levels but no increased
risk of ischemic events in patients undergoing elective percutaneous coronary intervention.
This identifies soluble glycoprotein VI as a potential biomarker that warrants deeper
investigation to assess its viability as a tool for personalized patient care.
New Mechanisms
The debate on whether statins offer additional benefits beyond low-density lipoprotein
(LDL) reduction was addressed by the study from Harm et al[72] who identified a distinct platelet lipid composition from statin-treated patients
with symptomatic coronary artery disease, offering valuable understanding into the
impact of statins that extends beyond mere LDL reduction. They discovered substantial
changes in platelet membrane lipids, which might contribute to statins' additional
effects. This study offers insights for future lipid studies, hinting at novel approaches
to target lipids beyond simplistic increase or decrease strategies.[73] Chen et al[74] underscored the formation of neo-vessels within vasa vasorum in large arteries of
type 2 diabetes patients, potentially contributing to atherosclerosis within the host
vessel. Insights into neo-vessel formation in vasa vasorum could aid in identifying
early vascular wall changes and determining suitable interventions to counter the
development of atherosclerotic lesions.[75] High-fat diet encourages the formation of atherosclerotic plaques within the inner
layer of arteries. Bianchini et al[76] investigated the impact of high-fat diet on bone marrow, using advanced imaging
techniques and found that just 1 week of high-fat diet altered arteriole structures
and hematopoiesis. Remarkably, these changes persisted even after 3 weeks on a normal
diet, raising questions about its rapid influence of diet on hematopoiesis and long-term
physiological alterations. The elevated numbers of neutrophils and monocytes also
observed in the bone marrow pointed toward an alteration of the inflammatory response.
The impact of another inflammatory mechanism, namely, tissue factor expression in
monocytes and its induction by lipopolysaccharide in a spectrum of disease, was the
topic of the comprehensive review by Sachetto and Mackman.[77] Encompassing sepsis and venous thrombosis, this study offers valuable insights into
these pathological conditions. Platelet procoagulant physiology and its related abnormalities
naturally continue to represent a dynamic focus of research published in TH. Recently,
immature reticulated platelets gained attention for their potential prognostic role
in cardiovascular diseases, especially coronary artery disease. A systematic review
by Bongiovanni et al[78] found a link between higher reticulated platelets and increased risk of major adverse
cardiovascular events in acute and chronic coronary syndrome patients. While promising,
using reticulated platelets as a routine prognostic tool requires further research
to establish optimal parameters and cutoff values as well as to understand how different
antiplatelet therapies affect patients with elevated reticulated platelets.[79] Kawano et al[80] developed a new mouse model using BxPC-3 cells to study pancreatic cancer's effect
on altered platelet function and arterial thrombosis. They found reduced platelet
counts but elevated reticulated platelets suggesting enhanced clearance of activated
platelets. Gui et al[81] introduced a valuable PDE5A knockout mouse model which enabled them to identify
PDE5A as a crucial enzyme for countering nitric oxide-induced platelet inhibition,
leading to smaller clots and prolonged bleeding. The model should aid unraveling the
complexities of cyclic nucleotide signaling pathways in platelets as well as evaluating
therapeutic interventions targeting these pathways. The paper from Seidizadeh et al[82] investigated the mechanisms behind low VWF, a condition prevalent among many individuals
who do, however, not all experience bleeding. The study revealed that diminished VWF
synthesis/secretion and increased VWF clearance play contributing roles.[83] Importantly, Bourne et al[84] alerted to CLEC-2's distinct role in mouse and human platelets. While CLEC-2 is
vital for thrombus growth in mice, it appeared to be less crucial for human platelet
thrombus formation under arterial shear, raising key questions about CLEC-2's biological
role in mice versus humans. Understanding species differences, as demonstrated in
this study, is naturally crucial for identifying meaningful therapeutic targets with
clinical use.[85] Other studies focused on specific mechanisms of the clotting process. Machado et
al[86] highlighted the importance of manipulating factor FIX interactions with endothelial
cells and connective tissue for clotting function. They demonstrated in two animal
models that FIX mutants favoring extracellular binding improved hemostasis in comparison
to other variants. Extravascular clotting activity of FIX and the underlying mechanism
still need to be determined as well as clinical relevance.[87] In a thorough biochemical analysis, Souri et al[88] identified an anti-FXIII-B alloantibody, which developed in an FXIII-B-deficient
patient after multiple plasma-derived FXIII concentrate treatments. This study questions
the previous assumption that auto- and alloantibodies against FXIII-B lacked inhibitory
effects and suggests instead that it might indirectly neutralize FXIII-B by impeding
its binding to fibrinogen with important implications for successful treatment.[89]
As every year, we are pleased to have been able to share a range of scientific advancements
and clinical observations, illustrating the various dimensions of TH. This past year
has seen crucial investigations aimed at refining general clinical approaches to thrombosis,
as well as at paving the way for new strategies in targeting biomarkers and understanding
fundamental cardiovascular mechanisms. We are looking forward to the new and exciting
discoveries and subsequent studies that the upcoming year will bring!
